582 Results (Page 2 of 24)
US Markets Research Reports
US Hepatitis A Therapeutics Market Analysis
The US Hepatitis A Therapeutics Market was valued at $309.62 Mn in 2023 and is predicted to grow at a CAGR of 0.2% from 2023 to 2030 to $313.98 Mn by 2030. One of the key drivers of this industry includes disease prevalence and therapeutic demand, as evidenced by a 270% increase in reported cases to 12,474 in 2018, followed by a continued rise to 18,846 cases and above. The top players are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., etc.
US Frontotemporal Disorders Therapeutics Market Analysis
US Glioblastoma Multiforme Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Neurons in the frontal and temporal lobes of the brain are damaged in frontotemporal diseases (FTD), also known as frontotemporal dementia. As the patient population for FTD is growing, non-profit organisations, illness advocacy groups, and private organisations are currently concentrating on supporting treatment research. A major driver of the frontotemporal disorders treatment market growth is predicted to be the rising life expectancy rate, which is also expected to contribute to the increasing prevalence of neurological diseases among the older population. Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., and Teva Pharmaceuticals USA, Inc. are just a few of the well-known worldwide and local businesses that are examined in the competitive landscape.
US Sanfilippo Syndrome (MPS-III) Therapeutics Market Analysis
US Sanfilippo Syndrome (MPS-III) Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Sanfilippo Syndrome (MPS-III) Therapeutics is growing rapidly as a result of increase in research and development activities, patient support and advocacy programmes, launch of new emerging therapies, increase in healthcare spending globally. Phoenix Nest Inc, Allievex Corp, Amicus Therapeutics Inc, ArmaGen Inc, Esteve Pharmaceuticals SA, JCR Pharmaceuticals Co Ltd, M6P Therapeutics, Orchard Therapeutics Plc, Seelos Therapeutics, Inc., and BioStrategies LC are top key players operating in global Sanfilippo Syndrome (MPS-III) Therapeutics market.
US Pseudomonas Aeruginosa Infection Therapeutics Market Analysis
US Pseudomonas Aeruginosa Infection Therapeutics Market is projected to grow from $0.55 Bn in 2022 to $0.74 Bn by 2030, registering a CAGR of 3.7% during the forecast period of 2022-2030. Industry income is expected to increase as a result of increased pseudomonas aeruginosa infections, an ageing population, future innovative antibiotic formulations, an increase in patients, and greater public awareness of the infection. Major global players in Pseudomonas Aeruginosa Infection Therapeutics Market are Allergan, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck & Co.
US Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics Market Analysis
US Fibrodysplasia Ossificans Progressiva Therapeutics Market is projected to grow from $0.21 Bn in 2022 to $0.25 Bn by 2030, registering a CAGR of 2.0% during the forecast period of 2023 ? 2030. An estimated 1.36 per Mn persons are believed to have the ultra-rare condition fibrodysplasia osseous progressiva, which affects about 900 people worldwide. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva, increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Therapeutics Market.
US Lymphoma Therapeutics Market Analysis
US Lymphoma Therapeutics Market was valued at $2,914.80 Mn in 2023 and is predicted to grow at a CAGR of 6.30%from 2023 to 2030, to $4,470.35 Mn by 2030. The key drivers of this industry include the rising prevalence of lymphoma, growing label extension, strong product pipeline, and rising geriatric population. The industry is primarily dominated by Bristol-Myers Squibb Company, Celgene Corporation, Merck & Co., Inc., and F. Hoffmann-La Roche Ltd, among others.
US Virtual Clinical Trials Market Analysis
This report presents a strategic analysis of the US Virtual Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Virtual Clinical Trials Market, offering unmatched value, accuracy and expert insights.
US Growth Hormone Deficiency Clinical Trials Market Analysis
This report presents a strategic analysis of the US Growth Hormone Deficiency Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Growth Hormone Deficiency Clinical Trials Market, offering unmatched value, accuracy and expert insights.
US COVID-19 Clinical Trials Market Analysis
This report presents a strategic analysis of the US COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US COVID-19 Clinical Trials Market, offering unmatched value, accuracy and expert insights.
US Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Analysis
This report presents a strategic analysis of the US Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market, offering unmatched value, accuracy and expert insights.
US Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis
US Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).
US Constipation Therapeutics Market Analysis
US Constipation Therapeutics Market was valued at $7,644 Mn in 2022 and is estimated to reach $10,871 Mn in 2030, exhibiting a CAGR of 4.5% during the forecast period. The constipation therapeutics market is growing driven by the global rise in constipation prevalence associated with aging, sedentary lifestyles, and poor dietary habits, and further fuelled by an expanding elderly population more prone to chronic conditions. Key players in this industry include AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eisai Inc., Johnson & Johnson, Pfizer, Takeda Pharmaceutical, Teva Pharmaceutical, and The Mentholatum Company.
US Antiviral Drugs Market Analysis
This report presents a strategic analysis of the US Antiviral Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Antiviral Drugs Market, offering unmatched value, accuracy and expert insights.
US Ear Infection Therapeutics Market Analysis
US Ear Infection Therapeutics Market was valued at $4956 Mn in 2022, projected to reach $6376 Mn by 2030 with a 3.2% CAGR. The rising prevalence of ear infections, particularly in children, is a key driver for the growth of the ear infection therapeutics market, as the increased incidence fosters a demand for effective solutions, propelling research, development, and market availability of treatments to address this widespread medical condition. Key players in this industry include Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Eli Lilly, Sandoz, Teva Pharmaceutical, Mylan, Hikma Pharmaceuticals, and Sun Pharmaceutical.
US Over The Counter (OTC) Analgesics Market Analysis
This report presents a strategic analysis of the US Over The Counter (OTC) Analgesics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Over The Counter (OTC) Analgesics Market, offering unmatched value, accuracy and expert insights.
US Cold Pain Therapy Market Analysis
The US Cold Pain Therapy Market was valued at $0.924 Bn in 2022 and is predicted to grow at a CAGR of 3.2% from 2023 to 2030, to $1.189 Bn by 2030. The key drivers of this industry include the increasing burden of pain disorders, increased demand for non-opioid alternatives, technological advancements, and others. The industry is primarily dominated by players such as Zimmer, Polar Products, Rapid Aid, Ossur, Chattanooga, and Medtronic among others.
US Blockchain Technology in Healthcare Market Analysis
This report presents a strategic analysis of the US Blockchain Technology in Healthcare Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the US Blockchain Technology in Healthcare Market, offering unmatched value, accuracy and expert insights.
US Electronic Records Management Solutions Market Analysis
The US electronic records management solutions market size was valued at $xx Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of xx% from 2022 to 2030 and will reach $xx Mn in 2030. The market is segmented by solution and deployment. US’s Electronic Records Management Solutions market will grow as the US government has a number of requirements that call on businesses to keep their electronic documents safe and easy to access. The key market players are Access (USA), Alfresco (USA), Box (USA), Hyland Software (USA), IBM (USA), and others.
US Nutritional Supplements Market Analysis
By 2030, it is anticipated that the US Nutrition and Supplements market will reach a value of $265.18 Bn from $160.23 Bn in 2022, growing at a CAGR of 6.5% during 2022-30. The market is primarily dominated by local players such as Amway, Herbalife Nutrition, and GNC Holdings. The market for Nutrition and supplements in the US is primarily driven by government regulations, increasing customer awareness, and e-commerce platforms. The US nutrition and supplements market in the US is segmented by Type, Product, application, and Distribution Channel.
US Mucopolysaccharidosis I (MPS-I) Therapeutics Market Analysis
US Mucopolysaccharidosis I (MPS-I) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in this market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
US Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
US Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
US Cholesterol Therapeutics Market Analysis
The US Cholesterol Therapeutics Market is anticipated to experience a growth from $10.206 Bn in 2022 to $10.706 Bn by 2030, with a CAGR of 0.6% during the forecast period of 2022-2030. The key drivers fueling the growth of this market include the increasing prevalence of cardiovascular diseases linked to elevated cholesterol levels, ongoing advancements in research and development leading to new medications, and heightened awareness among the population, prompting early detection and intervention through screening programs. The US Cholesterol Therapeutics Market encompasses various players across different segments, Pfizer, Amgen, Merck, AstraZeneca, Johnson & Johnson, Eli Lilly, Novartis, Sanofi, AbbVie, Regeneron, etc., among various others.
US Artificial Intelligence (AI) in Medical Imaging Market Analysis
The US Artificial Intelligence (AI) in Medical Imaging market size was valued at $630 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 33.4% from 2022 to 2030 and will reach $6318 Mn. The market is segmented by AI technology, solution, modality, application, and end user. The US Artificial Intelligence (AI) in the Medical Imaging market will grow due to Increasing demand for remote radiology services. Some of the key players in this market are Microsoft (US), NVIDIA (US), IBM (US), Intel Corporation (US), Google, Inc. (Subsidiary of Alphabet, Inc) (US), GE Healthcare (US), Digital Diagnostics, Inc (US), Xilinx (US), InformAI LLC (US), HeartFlow, Inc (US), Enlitic, Inc (US), Day Zero Diagnostics, Inc(US), Butterfly Network, Inc. (US), and others.
US Dental Care Market Analysis
The US Dental Care Industry Market size was valued at $15.07 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.4% from 2022 to 2030 and will reach $21.27 Bn in 2030. Some of the factors contributing to the rise in the market rise are the increasing number of dental-insured people and increasing income levels. A few key players in the Us dental care industry are Procter & Gamble, Johnson & Johnson, and Colgate-Palmolive Company.
US Retail Pharmacy Market Analysis
The US Retail Pharmacy Market is projected to grow from $436.2 Bn in 2022 to $639.6 Bn by 2030, registering a CAGR of 4.9% during the forecast period of 2022 - 2030. The growing demand for convenience in healthcare is driving the retail pharmacy market as more people are looking for ways to easily access and manage their medications. There are some of the major companies operating in the US Retail Pharmacy Market include CVS Health, Walgreens Boots Alliance, Rite Aid, and Walmart.